Beyond Air
Beyond Air, Inc.: A US-Israeli medical device and biopharma firm innovating nitric oxide treatments for respiratory diseases.
Founded
2011Beyond Air, Inc.: A US-Israeli medical device and biopharma firm innovating nitric oxide treatments for respiratory diseases.
Founded with a mission to revolutionize respiratory disease treatment, Beyond Air, Inc. is a medical device and biopharmaceutical company operating in the United States and Israel. The company focuses on the discovery and development of nitric oxide formulations and delivery systems, primarily through its LungFit® technology, which generates unlimited, on-demand nitric oxide from room air without the need for cylinders. Beyond Air aims to provide innovative, hassle-free solutions for both hospital and home settings, enhancing patient care and expanding treatment options.
Notable figures affiliated with Beyond Air include David Webster, who serves as the Chief Commercial Officer. The company has achieved significant milestones, such as presenting first-in-class clinical data demonstrating an immunogenic response in subjects with unresectable solid tumors. Beyond Air's impact lies in its pioneering approach to nitric oxide therapy, which has the potential to transform respiratory disease management and improve patient outcomes globally.
Companies similar to Beyond Air include Third Pole, Vero Biotech, Respirogen and Origin.
Beyond Air was founded in 2011.
Beyond Air's headquarters is located in New York City, NY, US.
Beyond Air's most recent funding round was for $40M (USD) in June 2023.
As of Jun 15, 2023, Beyond Air has disclosed funding of $69.2M (USD). Undisclosed round amounts are excluded.
Beyond Air has 98 employees as of Feb 5, 2024.
Origin
originww.com
